Related Experiment Video
Updated: Jul 16, 2026
A Neonatal Rodent Model of Retroorbital Vein Injection
Published on: February 23, 2024
Safety of high-dose recombinant erythropoietin in a neonatal rat model
Ronald J McPherson1, Eric J Demers, Sandra E Juul
1Department of Pediatrics, Division of Neonatology, University of Washington, Seattle, WA98195-6320, USA.
Insights
High-dose recombinant erythropoietin (rEpo) is safe for neonatal rats, improving development and preventing brain injury. This study shows rEpo enhances neurologic outcomes in newborns exposed to hypoxia or hypoxic-ischemic events.
Area of Science:
- Neonatal neuroscience
- Neuroprotection research
- Developmental biology
Background:
- High-dose recombinant erythropoietin (rEpo) demonstrates neuroprotective effects in neonatal animal models of brain injury.
- Long-term consequences of neonatal rEpo exposure remain understudied.
Purpose of the Study:
- To test the hypothesis that multiple high-dose rEpo injections in neonates are safe.
- To determine if neonatal rEpo improves neurologic outcomes following hypoxia or hypoxic-ischemic injury.
Main Methods:
- Sprague-Dawley rats were divided into normoxia, hypoxia, and hypoxia-ischemia groups.
- Neonates received varying doses of rEpo or vehicle subcutaneously during the first five days of life.
- Animals underwent specific hypoxia or hypoxia-ischemia protocols, with outcomes assessed physiologically and behaviorally.
Main Results:
- rEpo treatment transiently increased hematocrit and prevented hypoxia-induced developmental delays.
- Improved forelimb strength, enhanced liver growth in males, and reduced adult platelet count were observed.
- rEpo prevented learning impairments and substantia nigra neuron loss in hypoxia-ischemia models.
Conclusions:
- Repeated high-dose rEpo administration was safe in newborn rats across all tested conditions.
- rEpo treatment positively impacted the development of newborns exposed to hypoxia.
- Neonatal rEpo prevented learning deficits and dopamine neuron loss resulting from hypoxic-ischemic brain injury.
Background:
High-dose recombinant erythropoietin (rEpo) is neuroprotective in neonatal animal models of brain injury, but the long-term consequences of neonatal exposure have not been studied.
Objectives:
We hypothesized that multiple injections of high-dose rEpo during the neonatal period would be safe, and would improve neurologic outcomes after exposure to neonatal hypoxia or hypoxic-ischemic injury.
Methods:
Three experimental groups of Sprague-Dawley rats were assessed: (1) normoxia, (2) hypoxia and (3) hypoxia-ischemia. Groups 1 and 2 were given 0, 2,500 or 5,000 U/kg rEpo subcutaneously for the first 5 days of life (P1-P5). Group 2 animals also underwent 2 h of hypoxia (8% O(2)) daily from P1-P3. Group 3 animals underwent right carotid artery ligation followed by hypoxia (8% O(2) x 90 min) on P7, followed by either vehicle or rEpo (2,500 U/kg subcutaneously QD x3). We evaluated short- and long-term physiologic and behavioral outcomes. Major organs were evaluated grossly and histologically.
Results:
rEpo treatment transiently raised hematocrit, prevented hypoxia-induced delays in geotaxis and growth, improved forelimb strength, promoted liver growth in males, lowered the adult platelet count, but did not alter other CBC indices or histology. rEpo prevented hypoxia-ischemia-induced learning impairment and substantia nigra neuron loss.
Conclusions:
Repeated treatment of newborn rats with high-dose rEpo was safe under all conditions tested. rEpo treatment improved the development of hypoxia-exposed newborns and prevented the learning impairment and dopamine neuron loss due to unilateral hypoxic-ischemic brain injury.
